Agenus has announced an exclusive global partnership with BAP Pharma to support authorized access programs for its investigational immunotherapy combination botensilimab (BOT) plus balstilimab (BAL). The collaboration is designed to streamline and expand patient access to the therapy through regulated early‑access pathways worldwide.
Under the agreement, BAP Pharma will serve as Agenus’ exclusive partner for coordinating global access program operations, including request management, logistics, and distribution. The partnership covers France’s government‑reimbursed Autorisation d’Accès Compassionnel (AAC) pathway, as well as named‑patient programs (NPPs) in select countries outside the United States, in accordance with local regulatory frameworks. [pharmiweb.com]
The move comes amid growing international physician interest in BOT+BAL, particularly for patients with advanced cancers who have exhausted standard treatment options. By strengthening the infrastructure around authorized access pathways, the collaboration aims to ensure compliant, timely, and patient‑focused availability of the investigational combination while clinical development continues.
Official Announcement and Industry Commentary
Agenus and BAP Pharma formally announced the exclusive global partnership through their official channels, confirming BAP Pharma’s role in supporting authorized global access programs for BOT+BAL, including France’s AAC pathway and named‑patient programs across selected international markets.
Agenus official X post:
Agenus and BAP Pharma announced an exclusive global partnership supporting authorized access programs for investigational BOT+BAL, including France’s AAC pathway and named-patient programs in select countries. Read release.
BAP Pharma official LinkedIn post:
We are proud to announce that BAP Pharma has been appointed as the exclusive global partner for the Agenus botensilimab (BOT) plus balstilimab (BAL) authorized global access programs.
BAP Pharma will serve as Agenus’ exclusive global partner for the coordination of BOT+BAL global access program operations, including program requests, case coordination, distribution logistics, and related payment processing.
This partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations.
Click here to read more about BAP Pharma’s exclusive partnership with Agenus.
BAP Pharma/LinkedIn
Following the announcement, BAP Pharma leadership emphasized the patient‑centric focus of the collaboration, highlighting the importance of providing compliant early access to promising investigational therapies for individuals with limited treatment options.
Bryant O’Neill – Business Development Manager, BAP Pharma
Access matters—especially when patients have limited or no treatment options.
We’re proud to share that BAP Pharma has been appointed as the exclusive global partner for Agenus’ botensilimab (BOT) plus balstilimab (BAL) Authorized Global Access Programs.
This partnership is focused on one clear goal: helping patients gain timely, compliant access to promising therapies through authorized pathways, where permitted by local regulations.
As global physician interest in BOT+BAL continues to rise, the Agenus–BAP Pharma partnership reflects a broader industry emphasis on structured, well‑governed access pathways that responsibly bridge clinical development and regulatory approval in oncology.
Watch OncoDaily TV’s informative video on BOT+BAL.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada